News
Heartflow's quarterly loss widened over the year-ago period, the healthcare company disclosed in its paperwork for a U.S.
Heartflow has filed for an initial public offering. The company recorded sales of $125.8 million and a net loss of $96.4 million last year, according to a filing with the Securities and Exchange ...
The U.S. IPO market is witnessing a renewed vigor as investors return following months of sluggish activity triggered by ...
Such well-funded companies are ripe targets for IPO. Heartflow has been venture-backed since 2009, ramped up the amounts it has raised consistently – with a $100+ million round that wrapped up ...
The firm found that companies tended to IPO at an age of about 10 years and after raising roughly $200 million. ... HeartFlow has a $1.56 billion valuation, according to PitchBook.
Heartflow Holding Inc. is aiming to bring its noninvasive, artificial intelligence (AI)-based test for coronary heart disease to more doctors and patients via a merger with Longview Acquisition Corp.
Heartflow Holding Inc (NYSE: HFLO) aims to bring its noninvasive, artificial intelligence (AI)-based test for coronary heart disease to more doctors and patients via a SPAC merger with Longview ...
HeartFlow says the report is “fundamentally flawed.” There are also many believers, like Robert D. Safian, a cardiologist at Beaumont Health in Royal Oak, Michigan, who has received $3,000 ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--HeartFlow, Inc. today announced the closing of its Series E financing, securing $240 million. The company will use the proceeds from this financing to ramp ...
HeartFlow is a software company that is helping to make those coronary CTA scans which are used in a minority of cases even better. Lewis: I think as is often the case with med tech companies, ...
HeartFlow Inc. has raised a fresh funding round that puts the company’s valuation over $1.5 billion. and Baillie Gifford led the a $240 million Series E, with participation from existing ...
Heartflow Holding Inc. is aiming to bring its noninvasive, artificial intelligence (AI)-based test for coronary heart disease to more doctors and patients via a merger with Longview Acquisition Corp.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results